Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Gilles Salles; Stephen J. Schuster; Sven De Vos; Nina D. Wagner-Johnston; Andreas Viardot; Kristie A. Blum; Christopher R. Flowers; Wojciech J. Jurczak; Ian W. Flinn; Brad S. Kahl; Peter Martin; Yeonhee Kim; Sanatan Shreay; Matthias Will; Bess Sorensen; Madlaina Breuleux; Pier Luigi Zinzani; Ajay K. Gopal

doi:10.3324/haematol.2016.151738

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Gilles Salles, Stephen J. Schuster, Sven De Vos, Nina D. Wagner-Johnston, Andreas Viardot, Kristie A. Blum, Christopher R. Flowers, Wojciech J. Jurczak, Ian W. Flinn, Brad S. Kahl, Peter Martin, Yeonhee Kim, Sanatan Shreay, Matthias Will, Bess Sorensen, Madlaina Breuleux, Pier Luigi Zinzani, Ajay K. Gopal

Research output: Contribution to journal › Letter › peer-review

63 Scopus citations

Original language	English
Pages (from-to)	e156-e159
Journal	Haematologica
Volume	102
Issue number	4
DOIs	https://doi.org/10.3324/haematol.2016.151738
State	Published - Mar 31 2017

Access to Document

10.3324/haematol.2016.151738

Cite this

Salles, G., Schuster, S. J., De Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., Flowers, C. R., Jurczak, W. J., Flinn, I. W., Kahl, B. S., Martin, P., Kim, Y., Shreay, S., Will, M., Sorensen, B., Breuleux, M., Zinzani, P. L., & Gopal, A. K. (2017). Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica, 102(4), e156-e159. https://doi.org/10.3324/haematol.2016.151738

@article{85e2462127004dcdb255f0a315e54740,

title = "Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study",

author = "Gilles Salles and Schuster, {Stephen J.} and {De Vos}, Sven and Wagner-Johnston, {Nina D.} and Andreas Viardot and Blum, {Kristie A.} and Flowers, {Christopher R.} and Jurczak, {Wojciech J.} and Flinn, {Ian W.} and Kahl, {Brad S.} and Peter Martin and Yeonhee Kim and Sanatan Shreay and Matthias Will and Bess Sorensen and Madlaina Breuleux and Zinzani, {Pier Luigi} and Gopal, {Ajay K.}",

note = "Funding Information: this study was supported by Gilead Sciences, Inc. Editorial assistance for the development of this manuscript was provided by Meryl Gersh, PhD, of AlphaBioCom, LLC, King of Prussia, PA, and funded by Gilead Sciences, Inc., Foster City, CA.",

year = "2017",

month = mar,

day = "31",

doi = "10.3324/haematol.2016.151738",

language = "English",

volume = "102",

pages = "e156--e159",

journal = "Haematologica",

issn = "0390-6078",

number = "4",

}

Salles, G, Schuster, SJ, De Vos, S, Wagner-Johnston, ND, Viardot, A, Blum, KA, Flowers, CR, Jurczak, WJ, Flinn, IW, Kahl, BS, Martin, P, Kim, Y, Shreay, S, Will, M, Sorensen, B, Breuleux, M, Zinzani, PL & Gopal, AK 2017, 'Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study', Haematologica, vol. 102, no. 4, pp. e156-e159. https://doi.org/10.3324/haematol.2016.151738

TY - JOUR

T1 - Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma

T2 - A subgroup analysis of a phase 2 study

AU - Salles, Gilles

AU - Schuster, Stephen J.

AU - De Vos, Sven

AU - Wagner-Johnston, Nina D.

AU - Viardot, Andreas

AU - Blum, Kristie A.

AU - Flowers, Christopher R.

AU - Jurczak, Wojciech J.

AU - Flinn, Ian W.

AU - Kahl, Brad S.

AU - Martin, Peter

AU - Kim, Yeonhee

AU - Shreay, Sanatan

AU - Will, Matthias

AU - Sorensen, Bess

AU - Breuleux, Madlaina

AU - Zinzani, Pier Luigi

AU - Gopal, Ajay K.

N1 - Funding Information: this study was supported by Gilead Sciences, Inc. Editorial assistance for the development of this manuscript was provided by Meryl Gersh, PhD, of AlphaBioCom, LLC, King of Prussia, PA, and funded by Gilead Sciences, Inc., Foster City, CA.

PY - 2017/3/31

Y1 - 2017/3/31

UR - http://www.scopus.com/inward/record.url?scp=85016993064&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.151738

DO - 10.3324/haematol.2016.151738

M3 - Letter

C2 - 27979923

AN - SCOPUS:85016993064

SN - 0390-6078

VL - 102

SP - e156-e159

JO - Haematologica

JF - Haematologica

IS - 4

ER -

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Access to Document

Other files and links

Cite this